SCHEMBL644331

SCHEMBL644331

O=CC1CCC(C(CCc2ccccc2)N2CCCC2)CC1

nearest known ligand 0.38

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.38
MAPT P10636 1/20 0.38
SLC6A3 Q01959 2/20 0.36
TSHR P16473 2/20 0.36
KDM4E B2RXH2 2/20 0.36
MCL1 Q07820 1/20 0.36
SIGMAR1 Q99720 1/20 0.36
ACE P12821 1/20 0.35
NPC1 O15118 1/20 0.35
TDP1 Q9NUW8 1/20 0.35
CYP1A2 P05177 1/20 0.35
CYP3A4 P08684 1/20 0.35
CYP2D6 P10635 1/20 0.35
CYP2C19 P33261 1/20 0.35
SLC18A2 Q05940 1/20 0.35
SLC6A4 P31645 2/20 0.35
SLC6A2 P23975 1/20 0.35
MEN1 O00255 1/20 0.35
KMT2A Q03164 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL644715 0.89 ALDH1A1 (0.41) ALDH1A1TSHRSIGMAR1MEN1KMT2A
SCHEMBL646835 0.84 KDM4E (0.34) ALDH1A1MAPTSLC6A3TSHRKDM4E
SCHEMBL2493193 0.84 KDM4E (0.34) ALDH1A1MAPTSLC6A3TSHRKDM4E
SCHEMBL646834 0.84 KDM4E (0.34) ALDH1A1MAPTSLC6A3TSHRKDM4E
SCHEMBL643236 0.82 ACE (0.40) SLC6A3TSHRKDM4EMCL1SIGMAR1
SCHEMBL645172 0.81 ACE (0.41) ALDH1A1MAPTSLC6A3TSHRKDM4E
SCHEMBL493284 0.81 SIGMAR1 (0.41) ALDH1A1MAPTSLC6A3TSHRKDM4E
SCHEMBL642907 0.80 SLC6A3 (0.37) SLC6A3TSHRKDM4ESIGMAR1CYP1A2
SCHEMBL646013 0.80 SIGMAR1 (0.41) ALDH1A1MAPTSLC6A3TSHRKDM4E
SCHEMBL644224 0.74 HTT (0.40) ALDH1A1MAPTSLC6A3TSHRSIGMAR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8119633-B2 N-{2-[2-(4-benzyl-4-hydroxy-piperidin-1-yl)-2-oxo-ethoxy]-ethyl}-N-ethyl-4-methoxy-2,3,6-trimethyl-phenylsulfonamide; condensing the N-carboxyalkyl phenylsulfonamide with the substituted piperidine; bradykinin receptor antagonists; analgesics; antidiabetics; angiogenesis inhibitors; rheumatic diseases GRUENENTHAL GMBH (DE) 2012-02-21 US disclosed
EP-2150530-B1 SUBSTITUTED SULFONAMIDE DERIVATIVES GRUENENTHAL GMBH (DE) 2011-10-26 EP disclosed
EP-2150530-A1 SUBSTITUTED SULFONAMIDE DERIVATIVES Grünenthal GmbH (DE) 2010-02-10 EP disclosed
US-20080312231-A1 Substituted Sulfonamide Compounds GRUENENTHAL GMBH (DE) 2008-12-18 US disclosed
WO-2008131947-A1 SUBSTITUTED SULFONAMIDE DERIVATIVES Grünenthal GmbH (DE) 2008-11-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080312231-A1 Substituted Sulfonamide Compounds SULT2A1, SULT1A1, SCN1A ALDH1A1 511/4885MAPT 2595/4885SLC6A3 935/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.